Kalmaro

Researchers are investigating the use of adjunctive clindamycin along with standard treatment for skin and soft-tissue infections caused by Staphylococcus aureus in patients from Sierra Leone. The study focuses on whether adding clindamycin, known for its toxin-suppressing properties, can speed clinical recovery and reduce the chance of infection recurrence. This open-label, randomized controlled trial is a phase 4 study involving 100 adult participants. Participants will be randomly assigned to receive either standard care alone or standard care plus clindamycin. Clindamycin will be given either orally at 450 mg three times daily or intravenously at 10 mg/kg per dose up to 600 mg four times daily, for up to 7 days. The study will be conducted at Masanga Hospital, with treatment starting within 72 hours of initial culture collection confirming S. aureus infection. During the study, participants will be followed up to assess clinical cure at 7 days after treatment. Researchers will monitor safety, feasibility, and effectiveness of the added clindamycin treatment. Follow-up visits can occur during hospital admission or at home. The study will collect clinical data and outcomes to determine if adjunctive clindamycin improves treatment results compared to standard care alone.